Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. [electronic resource]
Producer: 20101214Description: 4990-5001 p. digitalISSN:- 1557-3265
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Benzenesulfonates -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Growth Processes -- drug effects
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Drug Synergism
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- HCT116 Cells
- HT29 Cells
- Humans
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Quinazolines -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- biosynthesis
- Signal Transduction -- drug effects
- Sorafenib
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.